{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"65","upperLimit":"90","value":"80"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"40"}],"units":"Participants"}],"description":"Chemotherapy treatment was centrally reviewed for quality assurance and compliance once complete chemotherapy treatment data was received from sites.","dispersionType":"95% Confidence Interval","groups":[{"description":"Cervical patients receive Intensity Modulated Radiation Therapy (IMRT) + Chemotherapy (cisplatin)","id":"OG000","title":"Cervical Cancer: IMRT + Chemotherapy (Cisplatin)"}],"paramType":"NUMBER","populationDescription":"Eligible patients in the chemotherapy group (cervical cancer patients) who started study treatment","reportingStatus":"POSTED","timeFrame":"From start to end of chemotherapy, approximately five weeks from registration.","title":"Percentage of Cervical Carcinoma Patients That Were Chemotherapy Compliant","type":"SECONDARY","unitOfMeasure":"percentage of participants"}